Does combined therapy of Ca-channel blocker and angiotensin converting enzyme inhibitor exceed monotherapy in renal protection against hypertensive injury in rats?

@article{Kanno1996DoesCT,
  title={Does combined therapy of Ca-channel blocker and angiotensin converting enzyme inhibitor exceed monotherapy in renal protection against hypertensive injury in rats?},
  author={Yoshihiko Kanno and Hirokazu Okada and Hiromichi Suzuki and Hiroyuki Ikenaga and Naohito Ishii and Hiroshi Itoh and Takao Saruta},
  journal={Clinical and experimental hypertension},
  year={1996},
  volume={18 2},
  pages={243-56}
}
Either calcium channel blocker (CCB) or angiotensin converting enzyme inhibitor (ACEi) is used as an antihypertensive agent, and we are recommended to use them in combination to refractory hypertension with evidence dependent on clinical observations. We examined the renal protective effect of the combined therapy with calcium channel blocker (amlodipine) and angiotensin converting enzyme inhibitor (enalapril) against hypertensive renal injury in 5/6 nephrectomized spontaneously hypertensive… CONTINUE READING